Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter

Journal of the American College of Cardiology

Volumn 29, Issue 2, 1997, Pages 385-390

  Falk, Rodney H ^a   Pollak, Arthur ^a   Singh, Steven N ^a   Friedrich, Tilman ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DOFETILIDE; PLACEBO;

ACTION POTENTIAL; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; DOUBLE-BLIND METHOD; HEMODYNAMIC PROCESSES; HUMANS; PHENETHYLAMINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0031029739     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00506-2     Document Type: Article

References (31)

1. Coplen SE, Antman FM, Berlin JM, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for the maintenance of sinus rhythm after cardioversion. Circulation 1990;82:1108-16.
2. Reimold SC, Chalmers TC, Berlin JA, Antman EM. Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: observations on the role of trial design and implications of drug-related mortality. Am Heart J 1992;124:924-32.
3. Janse MJ. To prolong refractoriness or to delay conduction (or both)? Eur Heart J 1992;13 Suppl F:14-8.
4. Singh BN, Nademanee K. Control of arrhythmias by selective lengthening of cardiac repolarization: theoretical considerations and clinical observations. Am Heart J 1985;109:421-30.
5. Singh BN. When is QT prolongation antiarrhythmic and when is it proarrhythmic? Am J Cardiol 1988;63:867-69.
6. Tande RM, Bjornstad H, Refsum H. Rate dependent class III antiarrhythmic action, negative chronotropy and positive inotropy of a novel I-K blocking drug, UK-68,798; potent in guinea pig but no effect in rat myocardium. J Cardiovasc Pharmacol 1990;16:401-10.
7. Gwilt M, Arrowsmith JE, Blackburn KJ, Burges RA, Cross PE, Dalrymple HW, Higgins AJ. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991;256:318-24.
8. + current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:195-215.
9. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992;262:809-17.
10. Bashir V, Wong C, Nathan AW, Cobbe SM, Campbell RW, Rasmussen HS. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent in recurrent ventricular tachycardia [abstract]. Br Heart J 1992;68:116.
11. Brachman J, Haverkamp W, Johns J, Zehender M, Kingma HC, Wiecha J. The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia [abstract]. Circulation 1992;86 Suppl I:I-265.
12. Suttorp MJ, Polak PE, Van't Hof A, Rasmussen HS, Dunselman PH, Kingma JH. Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter. Am J Cardiol 1992;69:417-18.
13. Ghosh BK. Comparison of some approximate confidence intervals for the binomial parameter. J Am Stat Assoc 1979;74:894-900.
14. Falk RH, Knowlton AA, Bernard S, Gotlieb NE, Battinelli NJ. Digoxin for converting recent onset atrial fibrillation to sinus rhythm - a randomized, double-blinded trial. Ann Intern Med 1987;106:503-6.
15. Capucci A, Lanzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 1992;70:69-72.
16. Bianvoni L, Boccadame R, Pappabardo A, Gentili C, Pistolese M. Effectiveness of intravenous propafenone for cardioversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;64:335-8.
17. Sedgwick ML, Lip G, Rae AP, Cobbe SM. Chemical cardioversion of atrial fibrillation with intravenous dofetilide. Int J Cardiol 1995;49:159-66.
18. Kingma JH, Suttorp MJ. Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone and verapamil. Am J Cardiol 1992;70:56A-60A.
19. Crijns HJGM, VanGelder IG, Kingma JH, Dunselman PHJM, Gosselink ATM, Lie KI. Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug. Eur Heart J 1994;15:1403-8.
20. Kayden H, Brodie BB, Steele JM. Procainamide; a review. Circulation 1957;15:118-26.
21. Olshansky B, Okumura K, Hess PG, Henthorn RW, Waldo AL. Use of procainamide with rapid atrial pacing for successful conversion of atrial flutter to sinus rhythm. J Am Coll Cardiol 1988;11:359-64.
22. Cosio FG, Arribas F, Barbero J, Kallmeyer C, Giocolea A. Validation of double-spike electrogram as marker of conduction delay or block in atrial flutter. Am J Cardiol 1988;61:775-80.
23. Spinelli W, Hoffman FB. Mechanism of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents. Circ Res 1989;65: 1565-79.
24. Levine JH, Spear JF, Guarnieri T, et al. Cesium chloride-induced long QT syndrome: demonstration of afterdepolarization triggered activity in vivo. Circulation 1985;72:1092-103.
25. El-Sherif N, Zeiler RH, Crawlius W, Gough WB, Henkin R. QT prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarization. J Am Coll Cardiol 1989;14:252-7.
26. Tham TCK, MacLennan BA, Burke MT, Harron DWG. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK 68,798) in humans. J Cardiovasc Pharmacol 1993;21:507-12.
27. McKibbin JK, Pocock WA, Barlow JB, Millar RNS, Obel IWP. Sotalol, hypokalemia, syncope and torsade de pointes. Br Heart J 1984;51:157-62.
28. Hohnloser SH, Arendts W, Quart B. Incidence, type and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF [abstract]. PACE 1992;15:551.
29. Crijns HJGM, Kingma JH, Gosselink AT, Dalrymple HW, DeLangen CD, Lie K. Sequential biatrial bundle branch block during dofetilide a new class III antiarrhythmic agent in a patient with atrial fibrillation. J Cardiovasc Electrophys 1993;4:459-66.
30. Crijns HJGM, Kingma JH, Gosselink AT, Lie K. Comparison in the same patient of aberrant conduction and bundle branch reentry after dofetilide, a new selective class III antiarrhythmic agent. PACE 1993;16:1008-16.
31. Mortensen E, Yang T, Refsum H. Class III antiarrhythmic action and inotropy: effect of dofetilide in acute ischemic heart failure in dogs. J Cardiovasc Pharmacol 1992;19:216-21.